Magnetic resonance imaging in thyroid eye disease: Signal intensity ratio to measure disease activity.
作者信息
Rath Suryasnata
机构信息
L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
出版信息
Indian J Ophthalmol. 2022 May;70(5):1446-1447. doi: 10.4103/ijo.IJO_365_22.
Abstract
摘要
相似文献
1
Magnetic resonance imaging in thyroid eye disease: Signal intensity ratio to measure disease activity.
Indian J Ophthalmol. 2022 May;70(5):1446-1447. doi: 10.4103/ijo.IJO_365_22.
2
Ultrasonography compared to magnetic resonance imaging in thyroid-associated Graves' ophthalmopathy.
Arq Bras Endocrinol Metabol. 2011 Apr;55(3):184-8. doi: 10.1590/s0004-27302011000300002.
3
Extrathyroidal manifestations of thyroid disease: thyroid ophthalmopathy.
Neuroimaging Clin N Am. 2008 Aug;18(3):527-36, viii-ix. doi: 10.1016/j.nic.2008.03.003.
4
Triamcinolone for the Treatment of Graves Ophthalmopathy Tested With Short Tau Inversion Recovery Magnetic Resonance.
Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):22-24. doi: 10.1097/IOP.0000000000001125.
5
Euthyroid Graves' ophthalmopathy with negative autoantibodies.
J Natl Med Assoc. 2005 Nov;97(11):1547-9.
6
Magnetic Resonance Imaging in the Management of Thyroid Eye Disease: A Systematic Review.
Ophthalmic Plast Reconstr Surg. 2023 Dec 1;39(6S):S81-S91. doi: 10.1097/IOP.0000000000002511. Epub 2023 Dec 4.
7
A Review of Imaging Modalities in Thyroid-associated Orbitopathy.
Int Ophthalmol Clin. 2019 Fall;59(4):81-93. doi: 10.1097/IIO.0000000000000289.
8
Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy--a pilot study at 1.5 T.
Neuroradiology. 2010 Feb;52(2):91-7. doi: 10.1007/s00234-009-0590-z. Epub 2009 Sep 15.
9
Thyroid eye disease.
QJM. 2016 Jan;109(1):67-8. doi: 10.1093/qjmed/hcv165. Epub 2015 Oct 8.
10
Correlation Between Optical Coherence Tomography and Magnetic Resonance Imaging of Rectus Muscle Thickness Measurements in Graves' Ophthalmopathy.
J Pediatr Ophthalmol Strabismus. 2019 Sep 1;56(5):319-326. doi: 10.3928/01913913-20190607-01.
引用本文的文献
1
Corneal breakdown in thyroid eye disease: Presentation and outcomes over a decade.
Indian J Ophthalmol. 2025 Apr 1;73(4):567-576. doi: 10.4103/IJO.IJO_1067_24. Epub 2025 Mar 27.
2
Assessing the relationship between levator palpebrae superioris and thyroid-associated ophthalmopathy using the Dixon-T2WI sequence.
Front Endocrinol (Lausanne). 2024 May 28;15:1387217. doi: 10.3389/fendo.2024.1387217. eCollection 2024.
3
Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.
J Clin Med. 2023 May 1;12(9):3244. doi: 10.3390/jcm12093244.
本文引用的文献
1
Triamcinolone acetonide injection in the treatment of upper eyelid retraction in Graves' ophthalmopathy evaluated by 3.0 Tesla magnetic resonance imaging.
Indian J Ophthalmol. 2022 May;70(5):1736-1741. doi: 10.4103/ijo.IJO_2228_21.
2
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
3
Sight-Threatening Thyroid Eye Disease: Role of Diabetes Mellitus and Interaction with Other Risk Factors.
Ophthalmic Plast Reconstr Surg. 2021;37(4):352-360. doi: 10.1097/IOP.0000000000001871.
4
Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.
Jpn J Ophthalmol. 2015 Mar;59(2):124-30. doi: 10.1007/s10384-014-0365-x. Epub 2014 Dec 3.
5
Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score.
Neuroradiol J. 2013 Oct;26(5):555-64. doi: 10.1177/197140091302600509. Epub 2013 Nov 7.
6
Subconjunctival injection of triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease.
J Craniofac Surg. 2012 Nov;23(6):1755-8. doi: 10.1097/SCS.0b013e3182646043.
7
Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy.
Can J Ophthalmol. 2012 Feb;47(1):34-41. doi: 10.1016/j.jcjo.2011.12.005.
8
Graves' ophthalmopathy.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
9
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14. doi: 10.1046/j.1365-2265.1997.2331047.x.
10
Magnetic resonance imaging in thyroid eye disease.
Eye (Lond). 1996;10 ( Pt 5):617-9. doi: 10.1038/eye.1996.140.
Zotero 插件